Survodutide (BI 456906) is transforming the landscape of obesity and MASH treatment as a groundbreaking dual agonist that targets both GLP-1 and GCGR receptors, yielding remarkable weight loss and liver health benefits. Currently in Phase 3 trials, it promises a new era of metabolic management by harnessing the power of appetite control and increased energy expenditure.
Mechanism
Survodutide uniquely activates GLP-1 receptors to trigger satiety and insulin release, while also stimulating glucagon receptors for enhanced energy expenditure and lipid clearance. This dual mechanism strikes a balance between appetite suppression and metabolic enhancement, resulting in superior weight loss and liver fat reduction compared to traditional GLP-1 therapies.
Research
In Phase 2 trials, Survodutide demonstrated impressive results, with participants experiencing an average weight loss of 14.9% and resolution of MASH in up to 62% of cases. These outcomes surpass those of established GLP-1 agonists like semaglutide, underscoring Survodutide's potential in effective weight management and liver health.
Synergies
The combined action of GLP-1R and GCGR activation not only optimizes weight control but also fortifies liver health, offering comprehensive metabolic improvements. Ben IQ evaluates YOUR labs and goals to tailor the perfect stack for you.
Trade-Offs
Despite its promise, Survodutide may lead to gastrointestinal side effects, including nausea and diarrhea, which need to be considered individually. YOUR specific circumstances and data are crucial in navigating these trade-offs.